Involvement of spinal CC chemokine ligand 5 in the development of bone cancer pain in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 5, 2013, Pages 325-328

  Hang, Li Hua ^a   Shao, Dong Hua ^a   Chen, Zheng ^a   Chen, Yuan Feng ^a   Shu, Wei Wei ^a   Zhao, Zhi Guo ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NEUTRALIZING ANTIBODY; RANTES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HYPERALGESIA; INOCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINAL CORD DORSAL HORN; TIBIA;

RATTUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; BONE NEOPLASMS; CARCINOMA 256, WALKER; CHEMOKINE CCL5; DISEASE MODELS, ANIMAL; FEMALE; HYPERALGESIA; INJECTIONS, SPINAL; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIBIA;

EID: 84885478926     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12099     Document Type: Article

References (26)

1. Flemming K. The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Symptom Manage 2010;39:139-54.
2. Holzer P, Ahmedzai SH, Niederle N, Leyendecker P, Hopp M, Bosse B et al. Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 2009;5:145-51.
3. Middlemiss T, Laird BJ, Fallon MT. Mechanisms of cancer-induced bone pain. Clin Oncol (R Coll Radiol) 2011;23:387-92.
4. Kim CH. Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:343-61.
5. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002;22:1067-8.
6. Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012;72:6325-32.
7. Suffee N, Hlawaty H, Meddahi-Pelle A, Maillard L, Louedec L, Haddad O et al. RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 2012;15:727-44.
8. Oh SB, Tran PB, Gillard SE, Hurley RW, Hammond DL, Miller RJ. Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci 2001;21:5027-35.
9. Benamar K, Geller EB, Adler MW. Elevated level of the proinflammatory chemokine, RANTES/CCL5, in the periaqueductal grey causes hyperalgesia in rats. Eur J Pharmacol 2008;592:93-5.
10. Liou JT, Yuan HB, Mao CC, Lai YS, Day YJ. Absence of C-C motif chemokine ligand 5 in mice leads to decreased local macrophage recruitment and behavioral hypersensitivity in a murine neuropathic pain model. Pain 2012;153:1283-91.
11. Liou JT, Mao CC, Ching-Wah Sum D, Liu FC, Lai YS, Li JC et al. Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model. J Pain 2013;14:24-35.
12. Padi SS, Shi XQ, Zhao YQ, Ruff MR, Baichoo N, Pert CB et al. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain 2012;153:95-106.
13. Hang LH, Yang JP, Yin W, Wang LN, Guo F, Ji FH et al. Activation of spinal TDAG8 and its downstream PKA signaling pathway contribute to bone cancer pain in rats. Eur J Neurosci 2012;36:2107-17.
14. Zhang RX, Liu B, Wang L, Ren K, Qiao JT, Berman BM et al. Spinal glial activation in a new rat model of bone cancer pain produced by prostate cancer cell inoculation of the tibia. Pain 2005;118:125-36.
15. Hang LH, Shao DH, Chen Z, Sun WJ. Spinal RhoA/Rho Kinase Signaling Pathway may Participate in the Development of Bone Cancer Pain. Basic Clin Pharmacol Toxicol. doi:10.1111/bcpt.12069. [Epub ahead of print].
16. Kerdsan W, Thanoi S, Nudmamud-Thanoi S. Changes in the neuronal glutamate transporter EAAT3 in rat brain after exposure to methamphetamine. Basic Clin Pharmacol Toxicol 2012;111:275-8.
17. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med 2010;16:1248-57.
18. Petitjean H, Rodeau JL, Schlichter R. Interactions between superficial and deep dorsal horn spinal cord neurons in the processing of nociceptive information. Eur J Neurosci 2012;36:3500-8.
19. Honore P, Mantyh PW. Bone cancer pain: from mechanism to model to therapy. Pain Med 2000;1:303-9.
20. Schmidt BL, Hamamoto DT, Simone DA, Wilcox GL. Mechanism of cancer pain. Mol Interv 2010;10:164-78.
21. Mao-Ying QL, Zhao J, Dong ZQ, Wang J, Yu J, Yan MF et al. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun 2006;345:1292-8.
22. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR et al. Role of microglia in central nervous system infections. Clin Microbiol Rev 2004;17:942-64.
23. Ahn DK, Lee KR, Lee HJ, Kim SK, Choi HS, Lim EJ et al. Intracisternal administration of chemokines facilitated formalin-induced behavioral responses in the orofacial area of freely moving rats. Brain Res Bull 2005;66:50-8.
24. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 2001;166:552-8.
25. Sullivan NL, Eickhoff CS, Zhang X, Giddings OK, Lane TE, Hoft DF. Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation. J Immunol 2011;187:1358-68.
26. Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S. Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain 2010;149:305-15.